Home » Newsletters » BioWorld Science

BioWorld Science

July 29, 1997

View Archived Issues

Mylan enters distribution agreement for ranitidine

Repligen identifies angiogenic growth factor inhibitors

Merck KGaA discloses novel ET antagonists

RPR prepares novel transfection agents

Ilex Oncology: Q2 1997 highlights

Statins protect against stroke and CVD

InSite Vision: Q2 1997 highlights

Melarsoprol normalizes cytokine levels in human African trypanosomiasis

Roche seeks U.S. and European approval for Corange takeover

Unigene Laboratories and Parke-Davis to develop oral calcitonin for osteoporosis

Papaverine/phentolamine compared to PGE1 for erectile dysfunction

Advantage-24 safe for evaluation in HIV prevention

Picotamide suppresses ACE inhibitor-induced cough

Review of preclinical and clinical studies with xanomeline

SangStat Medical reports encouraging phase III results with Thymoglobulin

Talsaclidine: favorable preclinical and pharmacokinetic profile

Vivus launches new device for erectile dysfunction in the U.S.

Sepracor reports promising phase II results for norastemizole

Antiherpes activity of naturally occurring flavone alone and in combination with aciclovir

Pharmacopeia receives SBIR grant for development of plasmepsin inhibitors

Jenner licenses emulsion formulation from Walter Reed

D-Pharm reports results from toxicity study for neuroprotective compound

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...